Monday 16th November 2009 – Crospon, a medical device developer based in Galway is delighted to announce it has received the Overall Medical Technology Excellence Award and the Gold Award for Innovation and Research and Development at the Irish Medical Device Association Awards held on Thursday 12th of November at Dromoland Castle. The Irish Medical Devices Association (IMDA) is an IBEC group that represents the medical technology sector in Ireland, and the IMDA Industry Excellence Awards are supported by Enterprise Ireland and the IDA.
Crospon develops leading edge minimally invasive medical devices for monitoring, diagnosis and therapy in the gastroenterology area.
Commenting on the Award, John O’Dea, CEO, Crospon said, “We are in a critical phase of our development having recently established a US operation and launched the product into the European market. Recognition by the Irish Medical Device Association is a significant boost for Crospon and our EndoFLIP® system. Over the last number of years we have worked closely with IMDA and Enterprise Ireland and their assistance and advice has been vital to the development of Crospon and EndoFLIP® “.
2009 has been a landmark year for Crospon and its flagship gastroenterology product, EndoFLIP®. In June, Crospon announced that it had agreed a worldwide distribution deal for the EndoFLIP®. The agreement with Dutch company, Medical Measurement Systems, one of the world’s leading companies in the development and distribution of medical gastrodiagnostic systems resulted in the first customer shipments into Europe taking place in July.
The EndoFLIP® tool which is pending FDA approval was designed by Crospon to provide a more physiologically relevant diagnostic test for gastroesophageal reflux disease (GERD). Chronic GERD is a prevalent disorder reaching epidemic proportions worldwide that manifests itself as severe heartburn caused by stomach acid refluxing up into the oesophagus. Crospon’s development of the EndoFLIP® system was recognised with the 2009 European Gastroenterology Technology Implementation of the Year Award by Frost & Sullivan.
Earlier in the year, the Company also announced the establishment of a US operation in Carlsbad, California and that it had received CE Mark certification for the EndoFLIP® product in accordance with the European Medical Device Directive.
About Crospon
Established in 2006, Crospon is a medical device company focused on the monitoring and treatment of gastroesophageal reflux disorder (GERD). Company co-founder and CEO, John O’Dea, previously co-founded Caradyne, a respiratory products company which was acquired by Respironics Inc in 2004.
In 2008, Crospon announced that it had completed an additional funding round of €3.5m. This funding will be primarily used for the completion of development, manufacturing start-up and preparation to market of the EndoFLIP®system.
Crospon was awarded the Connaught Business Achievers Award for 2008 in the ‘Ones to Watch’ category and the company’s Smart Drug Delivery Patch in conjunction with HP was listed in Popular Science’s magazines annual ‘Best of What’s New’ for 2008.
